Citation Impact
Citing Papers
Phosphodiesterase-5 Inhibitor in Eisenmenger Syndrome
2006
Phase III Study Comparing Cisplatin Plus Gemcitabine With Cisplatin Plus Pemetrexed in Chemotherapy-Naive Patients With Advanced-Stage Non–Small-Cell Lung Cancer
2008 Standout
Tadalafil Therapy for Pulmonary Arterial Hypertension
2009 Standout
Early skin-to-skin contact for mothers and their healthy newborn infants
2016 Standout
Efficacy and Tolerability of Tadalafil for Treatment of Erectile Dysfunction in Men Taking Serotonin Reuptake Inhibitors
2011
Current oral treatments for erectile dysfunction
2002
Emerging Pharmacologic Approaches for the Treatment of Lower Urinary Tract Disorders
2004
Pancreatic cancer
2004 Standout
Testosterone Therapy in Men with Androgen Deficiency Syndromes: An Endocrine Society Clinical Practice Guideline
2010 Standout
Nitric oxide synthases: regulation and function
2011 Standout
Evaluation of the Efficacy and Safety of Once-a-Day Dosing of Tadalafil 5mg and 10mg in the Treatment of Erectile Dysfunction: Results of a Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial
2006
Phosphodiesterase-5 Inhibition: the Molecular Biology of Erectile Function and Dysfunction
2005
Update on Phosphodiesterase (PDE) Isoenzymes as Pharmacologic Targets in Urology: Present and Future
2006
Review of time of onset and duration of clinical efficacy of phosphodiesterase type 5 inhibitors in treatment of erectile dysfunction
2006
Phosphodiesterase Type 5 Inhibitors: State of the Therapeutic Class
2007
Cyclic Nucleotide Phosphodiesterases: Molecular Regulation to Clinical Use
2006 Standout
Antidepressants and sexual dysfunction
2006
Pharmacokinetic Interaction Between Tadalafil and Bosentan in Healthy Male Subjects
2008
Metastatic non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
2016 Standout
Differences in hemodynamic and oxygenation responses to three different phosphodiesterase-5 inhibitors in patients with pulmonary arterial hypertension
2004
Efficacy and Safety of Tadalafil Monotherapy for Lower Urinary Tract Symptoms Secondary to Benign Prostatic Hyperplasia: A Meta-Analysis
2013 Standout
Organic Causes of Erectile Dysfunction in Men Under 40
2013 Standout
Early Palliative Care for Patients with Metastatic Non–Small-Cell Lung Cancer
2010 Standout
Erectile Dysfunction and Lower Urinary Tract
2008
A multicentre phase II study of cisplatin and gemcitabine for malignant mesothelioma
2002
Overview of phosphodiesterase 5 inhibition in erectile dysfunction
2003
cGMP-Dependent Protein Kinases and cGMP Phosphodiesterases in Nitric Oxide and cGMP Action
2010 Standout
Efficacy of Sildenafil Citrate at 12 Hours after Dosing: Re-exploring the Therapeutic Window
2004
Tadalafil Improved Erectile Function at Twenty‐Four and Thirty‐Six Hours After Dosing in Men With Erectile Dysfunction: US Trial
2005
Cisplatin-Based Therapy for Elderly Patients With Advanced Non-Small-Cell Lung Cancer: Implications of Eastern Cooperative Oncology Group 5592, a Randomized Trial
2002
Physiology and Pathophysiology of Purinergic Neurotransmission
2007 Standout
Sexual dysfunction in men and women with endocrine disorders
2007
A phase 2 study of platinum and gemcitabine in patients with advanced salivary gland cancer
2009
Phase II study of pemetrexed disodium, a multitargeted antifolate, and cisplatin as first-line therapy in patients with advanced nonsmall cell lung carcinoma
2001
Microtubule-binding agents: a dynamic field of cancer therapeutics
2010 Standout
Chronic Treatment with Tadalafil Improves Endothelial Function in Men with Increased Cardiovascular Risk
2004
Treatment of Erectile Dysfunction in Patients with Cardiovascular Disease
2004
Time course of the interaction between tadalafil and nitrates
2003
Role of gemcitabine in cancer therapy
2005
Economic Evaluation of Gemcitabine Alone and in Combination with Cisplatin in the Treatment of Nonsmall Cell Lung Cancer
2002
The status of platinum anticancer drugs in the clinic and in clinical trials
2010 Standout
The Role of Nitric Oxide in Erectile Dysfunction: Implications for Medical Therapy
2006
Engineered Nanoparticles for Drug Delivery in Cancer Therapy
2014 Standout
Advances in Malignant Mesothelioma
2005 Standout
Molecular mechanisms that could contribute to prolonged effectiveness of PDE5 inhibitors to improve erectile function
2008
Phosphodiesterase 5 Inhibitors for Erectile Dysfunction
2005
Gemcitabine Combined With Oxaliplatin in Advanced Pancreatic Adenocarcinoma: Final Results of a GERCOR Multicenter Phase II Study
2002
Recent Fascinating Aspects of the CuAAC Click Reaction
2020 StandoutNobel
Gemcitabine Plus Vinorelbine Versus Vinorelbine Alone in Elderly Patients With Advanced Non–Small-Cell Lung Cancer
2000
Diabetic Neuropathies
2005 Standout
Diversity‐Oriented Syntheses by Combining CuAAC and Stereoselective INCIC Reactions with Peptides
2017 StandoutNobel
Phase III Study of Pemetrexed in Combination With Cisplatin Versus Cisplatin Alone in Patients With Malignant Pleural Mesothelioma
2003 Standout
Long-Term Safety and Efficacy of Tadalafil 5 mg Dosed Once Daily in Men with Erectile Dysfunction
2008
Child Health, Developmental Plasticity, and Epigenetic Programming
2010
ACC/AHA 2008 Guidelines for the Management of Adults With Congenital Heart Disease: Executive Summary
2008 Standout
Diversity Oriented Clicking (DOC): Divergent Synthesis of SuFExable Pharmacophores from 2‐Substituted‐Alkynyl‐1‐Sulfonyl Fluoride (SASF) Hubs
2020 StandoutNobel
Microvascular and Macrovascular Complications of Diabetes
2008 Standout
Once-Weekly Semaglutide in Adults with Overweight or Obesity
2021 Standout
The emergence of oral tadalafil as a once-daily treatment for pulmonary arterial hypertension
2010
Diabetic Neuropathies: Update on Definitions, Diagnostic Criteria, Estimation of Severity, and Treatments
2010 Standout
Physical illness in patients with severe mental disorders. I. Prevalence, impact of medications and disparities in health care
2011 Standout
Ca2+Sensitivity of Smooth Muscle and Nonmuscle Myosin II: Modulated by G Proteins, Kinases, and Myosin Phosphatase
2003 Standout
Treatment of Advanced Non–Small-Cell Lung Cancer in the Elderly: Results of an International Expert Panel
2005
Diversity Oriented Clicking (DOC): Divergent Synthesis of SuFExable Pharmacophores from 2‐Substituted‐Alkynyl‐1‐Sulfonyl Fluoride (SASF) Hubs
2020 StandoutNobel
Diabetic Neuropathy: A Position Statement by the American Diabetes Association
2016 Standout
Erectile Dysfunction in Diabetes Mellitus
2009
Biochemistry and Physiology of Cyclic Nucleotide Phosphodiesterases: Essential Components in Cyclic Nucleotide Signaling
2007 Standout
2014 AHA/ACC Guideline for the Management of Patients With Non–ST-Elevation Acute Coronary Syndromes
2014 Standout
American Society of Clinical Oncology Treatment of Unresectable Non–Small-Cell Lung Cancer Guideline: Update 2003
2003 Standout
MANAGEMENT OF ENDOCRINE DISEASE: Are all GLP-1 agonists equal in the treatment of type 2 diabetes?
2019
Works of Greg Anglin being referenced
Genomic Imprinting in Turner Syndrome: Effects on Response to Growth Hormone and on Risk of Sensorineural Hearing Loss
2006
Efficacy of tadalafil for the treatment of erectile dysfunction at 24 and 36 hours after dosing: a randomized controlled trial
2003
The influence of gemcitabine and cisplatin schedule on response and survival in advanced non-small cell lung cancer
2000
Effects of once‐weekly dulaglutide on kidney function in patients with type 2 diabetes in phase II and III clinical trials
2016
Low incidence of anti‐drug antibodies in patients with type 2 diabetes treated with once‐weekly glucagon‐like peptide‐1 receptor agonist dulaglutide
2016
Gemcitabine in the treatment of elderly patients with advanced non-small cell lung cancer.
1997
Efficacy and Safety of Tadalafil for the Treatment of Erectile Dysfunction: Results of Integrated Analyses
2002
Efficacy and Safety of Tadalafil for the Treatment of Erectile Dysfunction: Results of Integrated Analyses
2002
Effects of Tadalafil on Erectile Dysfunction in Men With Diabetes
2002